AMAL aims to tackle the obstacles for effective anti-cancer therapy by stimulating a patient’s immune system in a unique way.
KISIMA®, our unique proprietary protein-based immunisation platform is self-adjuvanting and delivers several antigens in one single vaccine.
We focus on the development of viable effective cancer therapies. Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of metastatic colorectal cancers.
Our strategy is to develop KISIMA® and its current indications in oncology through to phase II, in-house or through strategic partnerships.
AACR Annual Meeting 2018
14-18 April 2018 / Chicago / Illinois
Patricia Delaite and Elodie Belnoue attending
14th Annual PEGS Summit
1-5 May 2018 / Boston, MA / USA
Madiha Derouazi speaking
16th CIMT Annual Meeting
15-17 May 2018 / Mainz / Germany
Jean-François Mayol attending
Amal Therapeutics SA
c/o Fondation pour Recherches Médicales
64 av. de la Roseraie
Website by Instinctif Partners